Genomic Health launches Oncotype DX colon cancer test
This article was originally published in Clinica
Executive Summary
Genomic Health has launched worldwide its Oncotype DX test to assess the recurrence risk of colon cancer. The diagnostic, which analyses 12 genes, is intended for patients with stage II disease following surgery. These patients often receive chemotherapy, but only around 2-4% benefit. Identifying who is likely to experience a recurrence could help spare patients from treatment they do not need. Genomic Health (Redwood City, California) plans to present data from two studies of the test at the ASCO Gastrointestinal Symposium this month, showing its efficacy in stage II patients, and suggesting that it might also be useful in stage III disease. The company also markets an Oncotype DX test to predict the likelihood of recurrence of breast cancer.